China Blood Product Industry Report, 2014-2017
  • July 2014
  • Hard Copy
  • USD $2,800
  • Pages:140
  • Single User License
    (PDF Unprintable)       
  • USD $2,600
  • Code: ZYM056
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $4,050
  • Hard Copy + Single User License
  • USD $3,000

Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn’t cause major disruption to domestic blood products market, the total plasma volume in China blood products industry reduced by 2.8% year on year and total lot release volume declined by 7% from a year earlier in 2013, due to stock consumption, insufficient utilization of new plasma stations and production break of some companies (e.g. Guizhou Taibang Biological Products Co., Ltd and Guangdong Wellen Biological Pharmaceutical Co., Ltd. on account of upgrading and reconstruction, Shanghai RAAS Blood Products Co., Ltd. affected by floods).

However, some niche varieties of blood products, such as scarce human coagulation factor VIII, maintained higher growth in lot release volume. In 2013, the human coagulation factor VIII produced by Shandong Taibang and CNBG Shanghai Institute of Biological Products were approved for release and came into the market, making the lot release volume of the product during the same period amount to 526,000 bottles, soaring by 44.5% on year-on-year basis.

Because of robust demand from China blood products market, the total lot release volume of imported human albumin reached 14.39 million bottles (about 10g/bottle) in 2013, a year-on-year increase of 24.1%, accounting for 53.4% (45.3% in 2012) of the total lot release volume of human albumin during the same period. Assuming absolute superiority, Behring, Baxter, Grifols and Octapharma still held the ground as the top four exporters of human albumin to China.

Despite a slight year-on-year decline in output and sales volume, major Chinese blood products companies, by and large, maintained steady revenue growth in 2013, thanks to rising prices of blood products (the highest retail prices of fibrinogen and blood coagulation factor VIII rose over 50% year on year). China Biologic Products, Hualan Bio, Tiantan Biological Products, Shanghai RAAS and Yuanda Shuyang Pharmaceutical, which hold combined 60% of the total plasma volume, generated total revenue of about RMB4.2 billion in 2013, up 13.5% year on year. Among them, Shanghai RAAS, due to production halt caused by flood, earned only RMB496 million, down 25.1% year on year.
Attracted by national policy support and high market prosperity, qualified Chinese blood products companies are actively engaged in construction of new plasma stations, some of which are expected to collect plasma by the end of 2014. In June 2014, Wuhan Zhongyuan Ruide Biological Product Co., Ltd. (100% controlled by Humanwell Healthcare (Group) Co., Ltd.)’s plasmapheresis center in Chibi was approved to collect plasma; In May 2014, Hualan Bio’s plasma station in Hua County, Henan Province was approved to be set up; In April 2014, Hebei Da'an Pharmaceutical (90% stake controlled by Walvax Biotechnology Co., Ltd.) carried out on-site GMP compliance certification for its plasma station in Wei County; At the end of 2013, Guangdong Shuanglin Bio-pharmacy’s plasma stations in Xi County and Jiang County of Shanxi were completed.

In addition, as the Ministry of Health stipulates that the blood products production units with registered varieties of blood products less than 6, and the blood products production units, which undertake national planned immunization task, with registered varieties of blood products less than 5, shall not apply to set up new plasmapheresis centers. Therefore, some superior blood products companies are improving their competitiveness by acquiring small ones which have single product mix but plasma stations. In June 2013, Jiangxi Boya Bio-pharmaceutical Co., Ltd. acquired 32% stake in Zhejiang Haikang Biological Products Co., Ltd., which had two plasma stations and held 41.98% stake in Xinjiang Deyuan Bioengineering Co., Ltd., which possessed 6 plasma stations. In March 2013, Shanghai RAAS set about purchasing Zhengzhou Banghe Pharmaceutical (now known as Zhengzhou RAAS) with RMB1.8 billion, with capital settlement completed in January 2014.

?血制品 英文_副本.png

China Blood Products Industry Report, 2014-2017 focuses on the following:
20120114.gifMarket size, plasma volume, distribution of plasma stations, supply and demand, import and export, etc. of China blood products industry;
20120114.gifCompetitive landscape, policy environment, development forecast, etc. of China blood products industry;
20120114.gifSupply and demand, competitive landscape, etc. of 8 blood product segments, including human albumin, Human Immunoglobulin (pH4) for Intravenous Injection, blood coagulation factor and human rabies immunoglobulin (HRIG).
20120114.gifOperation, blood products business and development prospects of 12 major Chinese blood products companies.

1. Overview of Blood Product Industry
1.1 Definition
1.2 Classification
1.3 Recombinant Blood Products
1.4 Industry Chain
1.5 Features

2. Overview of China Blood Product Industry
2.1 Market Size
2.2 Development
2.3 Supply & Demand
2.3.1 Supply
2.3.2 Demand
2.4 Competition
2.5 Operating Environment
2.5.1 International Market
2.5.2 Policy Environment
2.5.3 Domestic Biopharmaceutical Market
2.6 Import & Export

3. Blood Product Market Segments in China
3.1 Human Albumin
3.1.1 Supply & Demand
3.1.2 Competitive Landscape
3.1.3 Development Prospects
3.2 Human Immunoglobulin (pH4) for Intravenous Injection
3.2.1 Supply & Demand
3.2.2 Competitive Landscape
3.3 Blood Coagulation Factor VIII
3.3.1 Supply & Demand
3.3.2 Competitive Landscape
3.3.3 Development Prospects
3.4 Hepatitis B Immunoglobulin
3.4.1 Supply & Demand
3.4.2 Competitive Landscape
3.5 Human Immunoglobulin
3.5.1 Supply & Demand
3.5.2 Competitive Landscape
3.6 Human Prothrombin Complex
3.6.1 Supply & Demand
3.6.2 Competitive Landscape
3.7 Tetanus Immunoglobulin
3.7.1 Supply & Demand
3.7.2 Competitive Landscape
3.8 Human Rabies Immunoglobulin
3.8.1 Supply & Demand
3.8.2 Competitive Landscape

4. Major Chinese Manufacturers
4.1 China Biologic Products Inc.
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Customers and Suppliers
4.1.5 R&D and Investment
4.1.6 Shandong Taibang Biological Products Co., Ltd.
4.1.7 Guizhou Taibang Biological Products Co., Ltd.
4.1.8 Xi'an Huitian Blood Products Co., Ltd.
4.1.9 Outlook and Prediction
4.2 Hualan Biological Engineering Inc.
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 Customers and Suppliers
4.2.6 R&D and Investment
4.2.7 Blood Products
4.2.8 Outlook and Prediction
4.3 Shanghai RAAS Blood Products Co., Ltd.
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 Customers and Suppliers
4.3.6 R&D and Investment
4.3.7 Outlook and Prediction
4.4 Beijing Tiantan Biological Products Co., Ltd.
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 Customers and Suppliers
4.4.6 R&D and Investment
4.4.7 Blood Products (Chengdu Rongsheng Pharmaceutical Co., Ltd.)
4.4.8 Outlook and Prediction
4.5 Zhenxing Biopharmaceutical and Chemical Co., Ltd.
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 Customers and Suppliers
4.5.6 R&D and Investment
4.5.7 Blood Products (Guangdong Shuanglin Bio-Pharmacy Co., Ltd.)
4.5.8 Outlook and Prediction
4.6 Jiangxi Boya Bio-Pharmaceutical Co., Ltd.
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 Customers and Suppliers
4.6.6 R&D and Investment
4.6.7 Outlook and Prediction
4.7 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
4.7.1 Profile
4.7.2 Blood Products
4.8 Shanghai Institute of Biological Products Co., Ltd.
4.8.1 Profile
4.8.2 Blood Products
4.9 Shanxi Kangbao Biological Product Co., Ltd.
4.9.1 Profile
4.9.2 Blood Products
4.10 Green Cross
4.10.1 Profile
4.10.2 Blood Products
4.11 Humanwell Healthcare Group Co., Ltd.
4.11.1 Profile
4.11.2 Operation
4.11.3 Blood Products (Wuhan Zhongyuan Ruide Biological Product Co., Ltd.)
4.12 Walvax Biotechnology Co, Ltd.
4.12.1 Profile
4.12.2 Operation
4.12.3 Blood Products (Hebei Da’an Pharmaceutical Co., Ltd.)

5. Summary and Forecast
5.1 Company Analysis
5.2 Forecast
Basic Components of Blood
Classification and Efficacy of Blood Products
Comparison between Gene Recombinant Blood Products and Traditional Blood Products
Comparison between Gene Recombinant Blood Products and Traditional Blood Products in China and Overseas
Blood Product Industry Chain
Prices of Some Blood Products in China, 2013
Market Size of Blood Products in China, 2003-2013
Lot Release Volume of Blood Products (by Product) in China, 2008-2013
Product Structure of Blood Products in China (by Lot Release Volume), 2009-2013 
Annual Plasma Volume in China, 2002-2013 
Geographical Distribution of Plasma Collection Stations in China as of June 2014
Main Blood Products with Medical Insurance Coverage in China
Comparison of Per Capita Usage of Blood Products in China and Developed Countries
Plasma Station Distribution, Plasma Volume and Blood Product Revenue of Major Blood Product Manufacturers in China, 2013
Product Structure of Global Blood Products
Blood Products on Sale in Foreign Countries
On-going Clinical Trial of New Indications Overseas
Global Blood Product Manufacturers
Major Policies on Blood Products in China
Price of Human Albumin in China, 2003-2012
Ratio of Domestically-produced to Imported Human Albumin in China (by Lot Release Volume), 2007-2013
Market Share of Major Human Albumin Manufacturers in China (by Lot Release Volume), 2008-2013
Comparison between Consumption of Human Immunoglobulin (pH4) for Intravenous Injection in China and the United States, 2010
Lot Release Volume and Growth Rate of Human Immunoglobulin (pH4) for Intravenous Injection in China, 2007-2013
Prices of Human Immunoglobulin (pH4) for Intravenous Injection in China and Other Countries
Market Share of Major Manufacturers of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2007-2013
Lot Release Volume and Growth Rate of Blood Coagulation Factor VIII in China, 2008-2013 
Market Share of Major Blood Coagulation Factor VIII Manufacturers in China (by Lot Release Volume), 2008-2013
Comparison between Human Blood Coagulation Factor VIII and Recombinant Blood Coagulation Factor VIII
Lot Release Volume and Growth Rate of Hepatitis B Immunoglobulin in China, 2009-2013
Market Share of Major Hepatitis B Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2013
Prices of Human Immunoglobulin in China by Dosage, 2013
Lot Release Volume and Growth Rate of Human Immunoglobulin in China, 2008-2013 
Market Share of Major Human Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2013
Lot Release Volume and Growth Rate of Human Prothrombin Complex in China, 2008-2013
Market Share of Major Human Prothrombin Complex Manufacturers in China (by Lot Release Volume), 2008-2013
Lot Release Volume and Growth Rate of Tetanus Immunoglobulin in China, 2008-2012
Market Share of Major Tetanus Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2013
Lot Release Volume and Growth Rate of Human Rabies Immunoglobulin in China, 2008-2013 
Market Share of Major Human Rabies Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2013
Equity Structure of China Biologic Products by the End of 2013
Revenue and Operating Income of China Biologic Products, 2007-2014
Gross Margin of China Biologic Products, 2011-2013
Revenue Breakdown of China Biologic Products by Product, 2011-2013
Revenue Structure of China Biologic Products by Product, 2010-2012
China Biologic Products’ Revenue from Top 5 Customers and % of Total Revenue, 2008-2013
R&D Costs and % of Total Revenue of China Biologic Products, 2010-2013
New Products of China Biologic Products under Research by the End of 2013
Lot Release Volume of Blood Products of Shandong Taibang, 2008-2013
Lot Release Volume of Blood Products of Guiyang Qianfeng, 2008-2013
Lot Release Volume of Blood Products of Xi’an Huitian Blood Products, 2008-2013
Revenue and Operating Income of China Biologic Products, 2012-2017E
Revenue and Operating Income of Hualan Biological, 2007-2013
Revenue Breakdown of Hualan Biological by Sector, 2007-2013
Revenue Breakdown of Hualan Biological by Product, 2007-2013
Gross Margin of Hualan Biological by Product, 2007-2012
Hualan Biological‘s Revenue from Top 5 Customers and % of Total Revenue, 2007-2013
Hualan Biological’ Procurement from Top Five Suppliers and % of Total Procurement, 2007-2012
R&D Costs and % of Total Revenue of Hualan Biological, 2007-2013
Varieties and Specifications of Blood Products of Hualan Biological
Plasma Collection Station Distribution of Hualan Biological by May 2014
Lot Release Volume of Blood Products of Hualan Biological, 2008-2012
Revenue from and Gross Margin of Blood Products of Hualan Biological, 2007-2013
Revenue and Gross Margin of Hualan Biological by Product, 2007-2013
Revenue and Operating Income of Hualan Biological, 2012-2017E
Distribution of Plasma Collection Stations of Shanghai RAAS by the End of 2013
Revenue and Operating Income of Shanghai RAAS, 2008-2014
Lot Release Volume of Shanghai RAAS’s Blood Products, 2008-2013
Operating Revenue Breakdown of Shanghai RAAS by Product, 2008-2013
Revenue Breakdown of Shanghai RAAS by Region, 2007-2013
Gross Margin of Shanghai RAAS by Product, 2007-2013
Shanghai RAAS’s Revenue from Top 5 Customers and % of Total Revenue, 2007-2013
Shanghai RAAS’s Procurement from Top 5 Suppliers and % of Total Procurement, 2007-2012
R&D Costs and % of Total Revenue of Shanghai RAAS, 2007-2013
Revenue and Operating Income of Shanghai RAAS, 2012-2017E
Major Shareholding Companies of Tiantan Biological and Their Revenue, Net Income, 2013
Revenue and Operating Income of Tiantan Biological, 2007-2014
Revenue Breakdown of Tiantan Biological by Sector, 2007-2013
Revenue Breakdown of Tiantan Biological by Region, 2007-2013
Gross Margin of Tiantan Biological by Sector, 2007-2013
Tiantan Biological’s Procurement from Top 5 Suppliers and % of Total Procurement, 2007-2013
Tiantan Biological’s Revenue from Top 5 Customers and % of Total Revenue, 2007-2013
Name List and Revenue Contribution of Tiantan Biological’s Top 5 Customers, 2013
R&D Costs and % of Total Revenue of Tiantan Biological, 2009-2013
Distribution of Blood Plasma Collection Stations of Tiantan Biological by the End of 2013
Revenue from and Gross Margin of Blood Products Business of Tiantan Biological, 2007-2012
Lot Release Volume of Blood Products of Tiantan Biological, 2008-2013
Revenue and Operating Income of Tiantan Biological, 2012-2017E
Revenue and Operating Income of Zhenxing Biopharmaceutical and Chemical, 2008-2014
Operating Revenue Breakdown of Zhenxing Biopharmaceutical and Chemical by Product, 2009-2013
Gross Margin of Zhenxing Biopharmaceutical and Chemical by Product, 2009-2013
Zhenxing Biopharmaceutical and Chemical’s Revenue from Top 5 Customers and % of Total Revenue, 2009-2013
Zhenxing Biopharmaceutical and Chemical’s Procurement from Top 5 Suppliers and % of Total Procurement, 2013
R&D Costs and % of Total Revenue of Zhenxing Biopharmaceutical and Chemical, 2009-2013
Progress of Products under Research of Zhenxing Biopharmaceutical and Chemical by the end of 2013
Plasma Volume of Shuanglin Bio-Pharmacy, 2010-2013
Distribution of Plasma Collection Stations of Shuanglin Bio-Pharmacy by the End of 2013
Lot Release Volume of Blood Products of Shuanglin Bio-Pharmacy, 2008-2013
Revenue from and Gross Margin of Blood Products Business of Zhenxing Biopharmaceutical and Chemical, 2009-2013
Revenue and Operating Income of Zhenxing Biopharmaceutical and Chemical, 2012-2017E
Plasma Collection Volume of Jiangxi Boya Bio-Pharmaceutical, 2008-2013 
Revenue and Operating Income of Jiangxi Boya Bio-Pharmaceutical, 2008-2014
Revenue Breakdown of Jiangxi Boya Bio-Pharmaceutical by Product, 2009-2013
Lot Release Volume of Main Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2011-2013
Operating Revenue Breakdown of Jiangxi Boya Bio-Pharmaceutical by Region, 2009-2013
Gross Margin of Jiangxi Boya Bio-Pharmaceutical by Product, 2009-2012
Jiangxi Boya Bio-Pharmaceutical’s Revenue from Top 5 Customers and % of Total Revenue, 2009-2013
Name List and Revenue Contribution of Jiangxi Boya Bio-Pharmaceutical’s Top 5 Customers, 2013
Jiangxi Boya Bio-Pharmaceutical’s Procurement from Top 5 Suppliers and % of Total Procurement, 2009-2012
R&D Costs and % of Total Revenue of Jiangxi Boya Bio-Pharmaceutical, 2009-2013
Revenue and Operating Income of Jiangxi Boya Bio-Pharmaceutical, 2012-2017E
Distribution of Blood Plasma Collection Stations of Yuanda Shuyang by the End of 2013
Lot Release Volume of Blood Products of Yuanda Shuyang, 2008-2013
Lot Release Volume of Blood Products of CNBG Shanghai Institute of Biological Products, 2008-2013
Distribution of Blood Plasma Collection Stations of CNBG Shanghai Institute of Biological Products by the End of 2012
Distribution of Blood Plasma Collection Stations of Shanxi Kangbao Biological Product by the End of 2013
Lot Release Volume of Blood Products of Shanxi Kangbao Biological Product, 2008-2013 
Distribution of Blood Plasma Collection Stations of Green Cross China by the End of 2013
Lot Release Volume of Blood Products of Green Cross China, 2008-2013
Revenue and Operating Income of Humanwell Healthcare (Group), 2009-2013
Lot Release Volume of Blood Products of Wuhan Zhongyuan Ruide Biological Product, 2008-2013
Production Industry Layout of Walvax Biotechnology
Revenue and Operating Income of Walvax Biotechnology, 2009-2014
Revenue Breakdown of Walvax Biotechnology by Sector, 2009-2013
Distribution of Plasma Stations of Major Blood Products Manufacturers in China by June 2014
Plasma Volume of Major Blood Products Manufacturers in China, 2013
Revenue from Blood Products of Major Blood Products Manufacturers in China, 2011-2013
Production Lines Comparison of Blood Products Manufacturers in China
China Blood Products Market Size, 2012-2017E
Gross Margin of Major Blood Products Manufacturers in China, 2011-2013

China Animal Vaccine Industry Report, 2019-2025

Chinese animal vaccine industry showed a CAGR of 8% between 2013 and 2017, but it was depressed by the outbreak of African Swine Fever in 2018 with the market size edging down 2.5% on an annualized ba...

China Blood Product Industry Report, 2020-2026

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimburseme...

China Vacuum Blood Collection Device Industry Report, 2019-2025

As laboratory medicine advances, favorable polices are issued and people live a better life and care more about their health, vacuum blood collection systems get increasingly used. In 2018, global vac...

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号